Erika Lerch

776 total citations
19 papers, 510 citations indexed

About

Erika Lerch is a scholar working on Oncology, Hematology and Molecular Biology. According to data from OpenAlex, Erika Lerch has authored 19 papers receiving a total of 510 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 8 papers in Hematology and 6 papers in Molecular Biology. Recurrent topics in Erika Lerch's work include Multiple Myeloma Research and Treatments (5 papers), Protein Degradation and Inhibitors (4 papers) and Peptidase Inhibition and Analysis (4 papers). Erika Lerch is often cited by papers focused on Multiple Myeloma Research and Treatments (5 papers), Protein Degradation and Inhibitors (4 papers) and Peptidase Inhibition and Analysis (4 papers). Erika Lerch collaborates with scholars based in Switzerland, Italy and Australia. Erika Lerch's co-authors include Ulrich R. Müller, Verena Briner, Christoph Henzen, Michele Ghielmini, Emanuele Zucca, Cristiana Sessa, Vittoria Espeli, Laura Negretti, Andrea Bordoni and Jonas Feilchenfeldt and has published in prestigious journals such as The Lancet, Blood and Clinical Cancer Research.

In The Last Decade

Erika Lerch

19 papers receiving 487 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Erika Lerch Switzerland 9 147 129 71 65 63 19 510
M Fujimoto Japan 9 36 0.2× 64 0.5× 26 0.4× 45 0.7× 53 0.8× 10 410
Benjamin Schrijver Netherlands 13 64 0.4× 23 0.2× 24 0.3× 92 1.4× 41 0.7× 29 545
Amal S. El‐Shal Egypt 14 44 0.3× 28 0.2× 23 0.3× 46 0.7× 23 0.4× 32 534
Mustafa Yılmaz Türkiye 13 42 0.3× 23 0.2× 118 1.7× 29 0.4× 21 0.3× 41 417
G. Hense Switzerland 5 14 0.1× 105 0.8× 84 1.2× 18 0.3× 26 0.4× 6 577
Ritva Peltomaa Finland 13 49 0.3× 6 0.0× 30 0.4× 54 0.8× 48 0.8× 27 571
S.J. Szefler United States 6 117 0.8× 43 0.3× 181 2.5× 9 0.1× 47 0.7× 11 549
Thomas Birkner Austria 11 15 0.1× 237 1.8× 34 0.5× 22 0.3× 11 0.2× 17 432
Amy Hughes United States 11 26 0.2× 19 0.1× 32 0.5× 55 0.8× 88 1.4× 27 506
F. Clark United Kingdom 16 463 3.1× 15 0.1× 38 0.5× 56 0.9× 28 0.4× 30 717

Countries citing papers authored by Erika Lerch

Since Specialization
Citations

This map shows the geographic impact of Erika Lerch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Erika Lerch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Erika Lerch more than expected).

Fields of papers citing papers by Erika Lerch

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Erika Lerch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Erika Lerch. The network helps show where Erika Lerch may publish in the future.

Co-authorship network of co-authors of Erika Lerch

This figure shows the co-authorship network connecting the top 25 collaborators of Erika Lerch. A scholar is included among the top collaborators of Erika Lerch based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Erika Lerch. Erika Lerch is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Zander, Thilo, Thomas Pabst, Sämi Schär, et al.. (2023). Alternate-day dosing of pomalidomide in relapsed/ refractory multiple myeloma: a multicenter, single-arm phase 2 trial. Leukemia. 37(3). 699–701. 1 indexed citations
2.
Samaras, Panagiotis, Mario Bargetzi, Daniel Betticher, et al.. (2019). Updated recommendations for diagnosis and treatment of plasma cell myeloma in Switzerland. Swiss Medical Weekly. 149(1314). w20031–w20031. 4 indexed citations
3.
Manz, Markus G., Christine Waibel, Clemens B. Caspar, et al.. (2019). Daratumumab for relapsed or refractory AL amyloidosis with high plasma cell burden. Hematological Oncology. 37(5). 595–600. 24 indexed citations
4.
5.
Samaras, Panagiotis, Mario Bargetzi, Daniel Betticher, et al.. (2015). Current status and updated recommendations for diagnosis and treatment of plasma cell myeloma in Switzerland. Swiss Medical Weekly. 145(708). w14100–w14100. 4 indexed citations
6.
Wannesson, Luciano, Mario Bargetzi, Anne Cairoli, et al.. (2012). Autotransplant for Hodgkin lymphoma after failure of upfront BEACOPP escalated (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisone). Leukemia & lymphoma. 54(1). 36–40. 4 indexed citations
7.
Taverna, Christian, Mario Bargetzi, Daniel Betticher, et al.. (2010). Integrating novel agents into multiple myeloma treatment – current status in Switzerland and treatment recommendations. Swiss Medical Weekly. 140(3738). w13054–w13054. 2 indexed citations
8.
Lerch, Erika, et al.. (2010). A Case of Lenalidomide-Induced Hypersensitivity Pneumonitis. Onkologie. 33(5). 249–252. 17 indexed citations
9.
10.
Lerch, Erika, Vittoria Espeli, Emanuele Zucca, et al.. (2009). Prognosis of Acute Myeloid Leukemia in the General Population: Data from Southern Switzerland. Tumori Journal. 95(3). 303–310. 25 indexed citations
11.
Siano, Marco, Erika Lerch, Laura Negretti, et al.. (2008). A Phase I-II Study to Determine the Maximum Tolerated Infusion Rate of Rituximab with Special Emphasis on Monitoring the Effect of Rituximab on Cardiac Function. Clinical Cancer Research. 14(23). 7935–7939. 25 indexed citations
12.
Ponti, Giovanni, Tiziana Venesio, Lorena Losi, et al.. (2007). BRAF Mutations in Multiple Sebaceous Hyperplasias of Patients Belonging to MYH-Associated Polyposis Pedigrees. Journal of Investigative Dermatology. 127(6). 1387–1391. 11 indexed citations
13.
Morschhauser, Franck, Paula Marlton, Umberto Vitolo, et al.. (2007). Interim Results of a Phase I/II Study of Ocrelizumab, a New Humanised Anti-CD20 Antibody in Patients with Relapsed/Refractory Follicular Non-Hodgkin’s Lymphoma.. Blood. 110(11). 645–645. 20 indexed citations
14.
15.
Gallerani, Elisa, Erika Lerch, Elena Romagnani, et al.. (2006). Thrombotic thrombocytopenic purpura associated with renal failure after autologous transplantation for multiple myeloma successfully treated with rituximab. European Journal Of Haematology. 77(6). 527–529. 10 indexed citations
16.
Ghielmini, Michele, Laura Negretti, Erika Lerch, et al.. (2005). Infusion Speed-Escalation Trial To Give Full-Dose Rituximab in One Hour without Steroids Pre-Medication.. Blood. 106(11). 2451–2451. 7 indexed citations
17.
Henzen, Christoph, et al.. (2000). Suppression and recovery of adrenal response after short-term, high-dose glucocorticoid treatment. The Lancet. 355(9203). 542–545. 214 indexed citations
18.
Lerch, Erika & Ulrich R. Müller. (1998). Long-term protection after stopping venom immunotherapy: Results of re-stings in 200 patients. Journal of Allergy and Clinical Immunology. 101(5). 606–612. 136 indexed citations
19.
Lerch, Erika, et al.. (1998). ["Epilepsia peruviana"].. PubMed. 128(41). 1559–1559. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by M Fujimoto Breakdown of academic impact, for papers by Benjamin Schrijver Breakdown of academic impact, for papers by Amal S. El‐Shal Breakdown of academic impact, for papers by Mustafa Yılmaz Breakdown of academic impact, for papers by G. Hense Breakdown of academic impact, for papers by Ritva Peltomaa Breakdown of academic impact, for papers by S.J. Szefler Breakdown of academic impact, for papers by Thomas Birkner Breakdown of academic impact, for papers by Amy Hughes Breakdown of academic impact, for papers by F. Clark
Rankless by CCL
2026